(R)-O-methylphenylglycinol | 64715-86-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (R)-O-methylphenylglycinol
• 英文别名: (R)-α-methoxymethylbenzylamine hydrochloride；(R)-2-Methoxy-1-phenylethanamine hydrochloride；(1R)-2-methoxy-1-phenylethanamine;hydrochloride
• CAS: 64715-86-2
• 化学式: C₉H₁₃NO*ClH
• 分子量: 187.669
• InChiKey: DLMKXYXAHHMDJR-FVGYRXGTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.75
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  35.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319

反应信息

• 作为反应物：
  描述：

  (R)-O-methylphenylglycinol 在 吡啶 、 bromoborane-dimethyl sulfide complex 、 1-羟基苯并三唑一水物 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Synthesis of a library of chiral α-amino acid-based borate counteranions and their application to copper catalyzed olefin cyclopropanation

  摘要：

  Twenty borate counteranions have been prepared from tartaric acid and alpha-amino acid derivatives. Ion pairing of these anions to a copper cation can be Used to induce enantioselectivity into the copper catalyzed cyclopropanation of styrene. Structural modification of the anion provides insight into the importance of each component of the counteranion in asymmetric induction. (C) 2005 Published by Elsevier Ltd.

  DOI：

  10.1016/j.tetasy.2005.04.004
• 作为产物：
  描述：

  盐酸1,4-二恶烷 、 N-t-butoxycarbonyl-(R)-alpha-methoxymethylbenzylamine 在 乙醚 作用下， 反应 1.0h， 生成 (R)-O-methylphenylglycinol
  参考文献：
  名称：

  Aspartyldipeptide derivatives and sweetener compositions containing the

  摘要：

  公式（I）的Aspartyldipeptide化合物：L-Asp-X-NH-C*R.sub.1 R.sub.2（I），其中R.sub.1是烷基或烷氧甲基，R.sub.2是苯基，苄基，环己基或环己基甲基，当R.sub.1是烷基时，C*具有（S）构型，当R.sub.1是烷氧甲基时，C*具有（R）构型，X是D-.alpha.-氨基酸残基，DL-.alpha.-氨基酸残基或环状或非环状.alpha.，.alpha.-二烯基氨基酸残基，L-Asp和X之间的键是.alpha.键；以及它们作为甜味剂组合物中的活性成分的用途。

  公开号：

  US05723165A1

文献信息

• Stereoselective Reactions. 25. Enantioselective Deprotonation of Prochiral 4-Substituted Cyclohexanones by Chiral Chelated Lithium Amides
  作者：Ryuichi Shirai、Daisaku Sato、Kazumasa Aoki、Masahide Tanaka、Hisashi Kawasaki、Kenji Koga

  DOI：10.1016/s0040-4020(97)00288-3

  日期：1997.4

  4-substituted cyclohexanones (4a∼d) by chiral chelated lithium amides (8a≈k) in the presence of excess trimethylsilyl chloride was realized to give the corresponding chiral silyl enol ethers (6a∼d) in up to 89% ee. It is shown that enantioselectivity of the reaction is dependent on the solvent used, but becomes almost independent on the solvent in the presence of HMPA. The sense of asymmetric induction

  在过量的三甲基甲硅烷基氯存在下，通过手性螯合锂酰胺（8a≈k）对前手性4-取代的环己酮（4a〜d）进行对映选择性去质子化反应，得到相应的手性甲硅烷基烯醇醚（6a〜d）的比例高达89％ ee。结果表明，反应的对映选择性取决于所用的溶剂，但在HMPA存在下，其对映选择性几乎与溶剂无关。不对称诱导的感觉可以与锂酰胺的手性碳在带有手性碳的酰胺氮上的构型相关。©1997爱思唯尔科学有限公司。
• Organic Compounds
  申请人：Ehara Takeru

  公开号：US20090192148A1

  公开（公告）日：2009-07-30

  The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds have the formula I′ wherein R1, R2, T, R3 and R4 areas defined in the specification.

  本发明涉及3,5-取代哌啶化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖肾素活性的疾病（=失调）；该类化合物用于制备治疗依赖肾素活性疾病的制剂；该类化合物用于治疗依赖肾素活性的疾病；包括3,5-取代哌啶化合物的制药配方和/或包括给予3,5-取代哌啶化合物的治疗方法，以及制造3,5-取代哌啶化合物的新型中间体和部分合成步骤。该化合物的式子为I'，其中R1、R2、T、R3和R4在规范中有定义。
• Novel aspartyldipeptide derivatives and sweetener
  申请人：Ajinomoto Co., Inc.

  公开号：EP0691346A1

  公开（公告）日：1996-01-10

  A low-calory sweetener is provided which is highly stable and safe and has a high sweetness potency. This sweetener comprises novel aspartyldipeptide derivatives of the following general formula (1) and their salts:         L-Asp-X-NH-C*HR₁R₂   (1) wherein R₁ represents an alkyl group having from 1 to 6 carbon atoms, or an alkoxymethyl group having from 2 to 7 carbon atoms; R₂ represents a phenyl group, a benzyl group, a cyclohexyl group, or a cyclohexylmethyl group; the structure having the C* atom is of an (S) form when R₁ is an alkyl group but is of an (R) form when R₁ is an alkoxymethyl group; X represents a residue of a D-α-amino acid or DL-α-amino acid, or a residue of a cyclic or acyclic α,α-dialkylamino acid having from 3 to 6 carbon atoms, when R₁ is an alkyl group, but X represents a residue of a D-α-amino acid or DL-α-amino acid, or a residue of a cyclic or acyclic α,α-dialkylamino acid having from 3 to 6 carbon atoms, when R₁ is an alkoxymethyl group; and the bond between L-Asp and X is an α-bond.

  本发明提供了一种低热量甜味剂，它具有高度稳定性和安全性，并具有较高的甜味效力。这种甜味剂包括以下通式（1）的新型天冬二肽衍生物及其盐类： L-Asp-X-NH-C*HR₁R₂ (1) 其中 R₁ 代表具有 1 至 6 个碳原子的烷基，或具有 2 至 7 个碳原子的烷氧基甲基；R₂ 代表苯基、苄基、环己基或环己基甲基；当 R₁ 为烷基时，具有 C* 原子的结构为 (S) 形式，但当 R₁ 为烷氧基甲基时，具有 C* 原子的结构为 (R) 形式；当 R₁ 是烷基时，X 代表 D-α-氨基酸或 DL-α-氨基酸的残余物，或具有 3 至 6 个碳原子的环状或非环状 α,α-二烷基氨基酸的残余物、但当 R₁ 为烷氧基甲基时，X 代表 D-α-氨基酸或 DL-α-氨基酸的残基，或具有 3 至 6 个碳原子的环状或非环状 α,α-二烷基氨基酸的残基；L-Asp 与 X 之间的键为α键。
• 3 , 5-substitued piperidine compounds as renin inhibitors
  申请人：Novartis AG

  公开号：EP2420491A1

  公开（公告）日：2012-02-22

  The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3, 5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds (which can also be present as salts) have the formula I' wherein R1, R2, T, R3, R4, R7 and R8 are as defined in the specification and R6 is OH.

  本发明涉及3,5-取代的哌啶化合物，这些化合物用于温血动物的诊断和治疗，特别是用于治疗依赖于肾素活性的疾病（=紊乱）；使用该类化合物制备药物制剂，用于治疗依赖于肾素活性的疾病；该类化合物在治疗依赖于肾素活性的疾病中的用途；包含 3,5-取代的哌啶化合物的药物制剂，和/或包括施用 3,5-取代的哌啶化合物的治疗方法，3,5-取代的哌啶化合物的制造方法，及其合成的新型中间体和部分步骤。 这些化合物（也可以以盐的形式存在）具有式 I' 其中 R1、R2、T、R3、R4、R7 和 R8 如说明书中所定义，R6 为 OH。
• 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS
  申请人：Novartis AG

  公开号：EP1968940A1

  公开（公告）日：2008-09-17